Establishment and biological characterization of paclitaxel-resistant cell line of human ovarian carcinoma

Fudan University Journal of Medical Sciences

Volumn 35, Issue 2, 2008, Pages 171-175

  Han, Li Mei ^a   Pan, Hong ^b   Fang, Xiao Ling ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Pharmaceutical Group Co Ltd   (China)

Author keywords

Cell line; Multidrug resistance; Ovarian neoplasms; Paclitaxel; Rhodamine 123

Indexed keywords

EID: 41849146037     PISSN: 16728467     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer [J]. BBA-Rev Cancer, 1996,1288(2):F37-F49.
2. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy [J]. Curr Pharm Design, 2006,12(3):273-286.
3. Lehnert M. Clinical multidrug resistance in cancer: A multi-factorial problem [J]. Eur J Cancer, 1996,32A(6):912-920.
4. Martin N, Catalin J, Blachon MF, et al. Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography [J]. J Chromatogr B, 1998,709(2):281-288.
5. Chinese source
6. Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells[J]. Biochem Pharmacol, 1997,53(4):461-470.
7. Sha XY, Fang ML. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs[J]. Int J Pharm, 2004,272(1-2):161-171.
8. Chinese source
9. Chinese source
10. Chinese source
11. De Paula SO, De Melo Lima C, Torres MP, et al. One-step RT-PCR protocols improve the rate of dengue diagnosis compared to two-step RT-PCR approaches [J]. J Clin Virol, 2004,30(4):297-301.
12. Chinese source
13. Chinese source
14. Stormer E, Perloff MD, Von Moltke LL, et al. Methadone inhibits rhodamine123 transport in Caco-2 cells [J]. Drug Metab Dispos, 2001,29(7):954-956.
15. Jin J, Wang FP, Wei HL, et al. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine [J]. Cancer Chemoth Pharm, 2005,55(2):179-188.
16. Sands H, Mishra A, Stoeckler JD, et al. Preclinical activity of an i. v. formulation of rubitecan in IDD-P (TM) against human solid tumor xenografts[J]. Anti-Cancer Drug, 2002,13(9):965-975.
17. Chinese source
18. Chinese source